COVID-19 | SAHPRA monitors C.1.2 variant
The South African Health Products Regulatory Authority (SAHPRA) Chair, Professor Helen Rees says the
J&J vaccine recipients will be informed of possibility of blood clots developing
The South African Health Products Authority (SAHPRA) says recipients of the Johnson and Johnson
COVID-19 vaccine’s positive effects outweighs the risk: SAHPRA
The South African Health Products Authority (SAHPRA) has sought to allay fears overtaking a vaccine
SAHPRA voices cautious optimism about Pfizer/BioNTech vaccine efficacy
The South African Health Products Authority (SAHPRA) has voiced cautious optimism over the efficacy
Experts closely monitoring health workers who received J&J vaccines: Rees
Experts are closely monitoring South African health workers who have received the Johnson and